🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New phase 2 trial of Zanubrutinib + Ixazomib + Dexamethasone in #WaldenstromsMacroglobulinemia shows a promising VGPR+ rate (46%), but median PFS of 40 mo is only slightly better than IDR and lower than current SOC. Will depth translate to durability in time-limited combos for

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance iStopMM JAMA Oncology #mmsm jamanetwork.com/journals/jamao… Important data coming to support need for new ranges of normal free light chains based on eGFR👇

🎗️ 10% Discount for European Students – Master’s in Molecular Oncology “This Master’s is absolutely essential for practising oncologists.” — Dr. Mariano Barbacid, AXA-CNIO Professor of Molecular Oncology and former Director of the Spanish National Cancer Research Centre (CNIO)

📖 Platelet disorders and treatments: a comprehensive review ⬇️ 📌 Zhang et al. review common causes of thrombocytopenia and thrombocytosis, and treatments for these two conditions Read on TH 👉 tinyurl.com/bddn7725 #Platelets #Hematology #Thrombosis

Latest issue of Bone Marrow Transplantation, a consensus paper on QC harmonization for 🇪🇺 locally-manufactured #CAR-T_cells rdcu.be/eostD Ibrahim Yakoub-Agha The EBMT ASH FOCIS International Union of Immunological Societies SFI Immunologie Monica Guzman Immunopaedia Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx Mohamad Mohty

#Myeloma Paper of the Day: New light chain #MGUS definition -> 1.54% prevalence (1.46-1.63) using standard & 0.27% (0.23-0.30) w/ revised intervals; 0/1006 persons meeting LC-MGUS criteria w/ standard but not based on revised intervals progressed: pubmed.ncbi.nlm.nih.gov/40440024/. #mmsm

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow ow.ly/Tr1Z50W11ag #bloodwork #myeloidneoplasia

🔬 Check out our latest work on the evolution of #MDS to #AML In this brief paper, we show how changes in MSC content measured by flow cytometry at diagnosis can help predict #Leukemia Tranformation. onlinelibrary.wiley.com/doi/10.1002/jh…

Metallica joins Jimmy Fallon and The Roots in the Tonight Show Music Room to perform "Enter Sandman" with classroom instruments

The incidence of Strongyloides infection among #lymphoma patients is significant and supports the implementation of routine #Strongyloides screening and targeted prophylaxis. doi.org/10.1002/ajh.27…

My Updated Myeloma Treatment Algorithms. #ASCO25 Bookmark! Presented at COMy. 1) Newly Diagnosed myeloma transplant ineligible.

2) Newly Diagnosed myeloma transplant eligible. #ASCO25

3) Relapsed Myeloma - First relapse. MSMART.org #ASCO25

4) Relapsed Myeloma - Refractory Second or Higher Relapse #ASCO25

5) The algorithms provide guidelines for treatment if certain drugs are not available or affordable. #ASCO25

Out now in Blood Journal, Lu et al 🙌🏽 Phase IIb Ven/Dec vs Intensive chemo (7&3) in younger adults with AML 💪🏽 1° end point: CRc after induction ➡️CRc 89% vs 79%, non inf p=0.002 💪🏽 ➡️Ven/Dec better tolerated 🙌🏽 #MedTwitter ashpublications.org/blood/article/…

#Myeloma Paper of the Day: Consensus Panel 3 from 12th International #Waldenström macroglobulinemia Workshop recommends risk stratifying smoldering & active WM, genetic alteration screening & risk-adapted approach w/ clinical trial participation: pubmed.ncbi.nlm.nih.gov/40441983/. #mmsm

#ASCO25 #mmsm check out our education chapter: Current and Future Directions of Immunotherapies in Multiple Myeloma ASCO ➡️ ascopubs.org/doi/10.1200/ED… My section focused on upfront quad therapy and when to consider triplet based therapy, check summary tables and figures👇

Vasculitis associated with VEXAS syndrome. pubmed.ncbi.nlm.nih.gov/39392442/ Mayo Clinic #VEXAS